<DOC>
	<DOCNO>NCT01117441</DOCNO>
	<brief_summary>Rationale/Purpose : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . It yet know combination chemotherapy regimen effective treat young patient acute lymphoblastic leukemia ( ALL ) . This trial study several different combination chemotherapy regimens compare well work treat young patient ALL . Study objectives Primary study question : - Non high-risk ( non-HR ) precursor-B ALL ( pB-ALL ) patient TEL/AML1-negative ALL unknown TEL/AML1 status flow cytometry minimal residual disease ( MRD ) bone marrow day 15 &lt; 0.1 % TEL/AML1-positive ALL ( randomize study question R1 ) : Can daunorubicin dose Protocol IA safely reduce 50 % non-inferior EFS reduction toxicity ( treatment-related mortality AE/SAE Protocol I ) ? - Patients pB-ALL risk group medium risk ( MR ) ( randomize study question R2 ) : Can clinical outcome improve protracted asparagine depletion achieve application intensify PEG-L-asparaginase reintensification early maintenance ? - High-risk ( HR ) patient ( identify day 33 - randomize study question RHR ) : Can clinical outcome improve protracted exposure PEG-L-asparaginase Protocol IB ? Secondary study question : - Standard risk ( SR ) patient identify least one sensitive marker : Is clinical outcome comparable obtain SR patient ( identify two sensitive marker ) AIEOP-BFM ALL 2000 , outcome even improve use PEG-L-asparaginase instead native E. coli L-ASP ? - T-ALL non-HR patient : Can high level outcome obtain patient study AIEOP-BFM ALL 2000 preserve even improve use PEG-L-ASP instead native E. coli L-ASP ? - HR patient persist high MRD level despite use HR block intensify consolidation phase `` MRD Non-Responders '' : Is possible improve outcome achieve reduction leukemic cell burden administration innovative treatment schedule ( DNX-FLA ) ? - Patients participate randomized asparaginase study ( pB-ALL/MR , HR ) : Are asparaginase activity asparaginase antibody associate development allergic reaction , effect outcome patient ? - What relative value different method MRD monitor definition alternative stratification system within BFM-oriented protocol ?</brief_summary>
	<brief_title>International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>Risk Stratification - T/non-HR : T-ALL absence HR criterion ( see ) - pB/non-HR : pB-ALL absence HR criterion ( see ) . - SR ( polymerase chain reaction ( PCR ) -MRD-SR ( MRD-negative day 33 78 ) , PCR-MRD result available , FCM d15 &lt; 0.1 % ) - MR ( SR ) - HR : Prednisone poor-response ( ≥1000 blast cells/µl peripheral blood day 8 ) , blast cell ≥10 % bone marrow day 15 measure FCM , non-remission day 33 , positivity MLL/AF4 ( 4 ; 11 ) , hypodiploidy ( &lt; 45 chromosome ) , PCR-MRD-HR ( MRD ≥10E-3 day 78 ) PCR-MRD-MR SER ( pB-ALL , MRD ≥ 10-3 day 33 MRD positive level &lt; 10E-3 day 78 ) Chemotherapy According risk group , patient receive follow chemotherapy element : T/non-HR : Protocol I , Protocol M , Protocol II Maintenance pB/non-HR : Protocol I , Protocol M , Protocol II Maintenance HR : Protocol I , HR-1 ' , HR-2 ' , HR-3 ' , 3x Protocol III , Maintenance Patients HR group PCR-MRD ≥10E-3 element HR-3 ' eligible treatment element DNX-FLA. Protocol I Cytoreductive prephase : Prednisone ( PDN ) day 1-7 one dose methotrexate ( MTX ) intrathecal ( IT ) day 1 Protocol IA : Prednisone ( PDN ) day 8 28 ( 21 day ) ; vincristine ( VCR ) day 8 , 15 , 22 , 29 ( 4 dos ) ; daunorubicin ( DNR ) day 8 , 15 , 22 29 ( 4 dos ) ; pegylated L-asparaginase ( PEG-L-ASP ) day 12 26 ; MTX IT day 12 33 case blast cell cerebrospinal fluid diagnosis additional IT MTX give day 19 26 . Protocol IA ' : Only two dos DNR day 8 15 give patient eligible randomization R1 randomize experimental arm Protocol IA-CPM : additional cyclophosphamide ( CPM ) day 10 T-ALL patient prednisone poor-response Protocol IA-Dexa ( IAD ) : Dexamethasone ( DXM ) instead PDN give patient T-ALL without high-risk criterion identify day 8 . Protocol IB : CPM day 36 64 ; cytarabine ( ARA-C ) day 38-41 , 45-48 , 52-55 59-62 ; 6-mercaptopurine ( 6-MP ) day 36 63 ( 28 day ) ; MTX IT day 45 59 Protocol IB-ASP+ : additional PEG-L-ASP day 40 , 47 , 54 , 61 ( 4 dos ) give patient eligible randomization RHR randomize experimental arm . Protocol M 6-MP day 1- 56 , high-dose MTX ( HD-MTX ) day 8 , 22 , 36 , 50 MTX IT day 8 , 22 , 36 50 Protocol II Protocol IIA : DXM day 1 21 ( 21 day ) ; VCR day 8 , 15 , 22 , 29 ( 4 dos ) ; doxorubicine ( DOX ) day 8 , 15 , 22 29 ( 4 dos ) ; PEG-L-ASP day 8 ( 1 dose ) ; MTX IT day 1 18 patient initial CNS involvement . Protocol IIA-ASP+ : additional PEG-L-ASP day 22 patient eligible randomization R2 randomize experimental arm . Protocol IIB : CPM day 36 ; ARA-C day 38-41 45-48 ; thioguanine ( TG ) day 36 49 ( 14 day ) MTX IT day 38 45 . Protocol IIB-ASP+ : additional PEG-L-ASP day 36 50 eligible randomization R2 randomize experimental arm . Protocol III DXM day 1-15 ; VCR day 1 8 ; DOX day 1 8 ; PEG-L-ASP day 1 ; CPM day 15 ; ARA-C day 17-20 24-27 ; TG day 15 - 28 MTX IT day 17 24 , also day 1 patient initial CNS involvement HR-1 ' DXM day 1-5 ; VCR day 1 6 ; HD-MTX day 1 ; CPM every 12 hour day 2-4 ( 5 dos ) ; HD-ARA-C every 12 hour day 5 ( 2 dos ) ; PEG-L-ASP day 6 , MTX IT day 1 HR-2 ' DXM day 1 5 ; VDS day 1 6 ; HD-MTX day 1 ; IFO every 12 hour day 2-4 ( 5 dos ) ; DNR day 5 ; PEG-L-ASP day 6 ; MTX IT day 1 1 patient initial CNS involvement also day 5 HR-3 ' DXM day 1-5 ; ARA-C 4 x day 1-2 12 h interval ; etoposide ( VP-16 ) every 12 hour day 3-5 ( 5 dos ) ; PEG-L-ASP day 6 ; MTX IT day 1 DNX-FLA Flucytosine ( FLU ) day 1-5 ( 5 dos ) ; HD-ARA-C day 1 5 ( 5 dos ) ; liposomal daunorubicin ( DNX ) day 1 , 3 5 ( 3 dos ) ; MTX IT day 1 Interim/Maintenance ( week 104 ) : 6-MP p.o . daily ; MTX p.o . week , dos adjust white blood cell count ; PEG-L-ASP : every second week ( 6 dos ) , patient eligible randomization R2 randomize experimental arm ; MTX IT every 6 week total 6 dos follow subgroup ( CNS-negative ) : - T-ALL ( HR non-HR ) &lt; 2 year age start maintenance , - T-ALL , non-HR initial WBC &lt; 100 000/μl - pB-ALL PPR and/or FCM-MRD day 15 ≥ 10 % and/or PCR-MRDMR SER HR criterion Radiotherapy Patients without CNS involvement - T-ALL/non-HR , WBC ≥ 100 000/μl , age ≥ 2 year start pCRT - risk group HR age ≥ 2 year start pCRT except pB-ALL PPR and/or FCM-MRD day 15 ≥ 10 % and/or PCR-MRD-MR SER HR criterion receive preventive cranial radiotherapy 12 Gy Patients CNS involvement receive therapeutic cranial radiotherapy 18 Gy ( age 1 &lt; 2 year 12 Gy ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>newly diagnose acute lymphoblastic leukemia age ≥ 1 year ( &gt; 365 day ) &lt; 18 year old ( 17 year old 365 day ) Ph+ ( BCR/ABL ( 9 ; 22 ) positive ) ALL evidence pregnancy lactation period participation another clinical study patient enrol participate center write informed consent pretreatment cytostatic drug pretreatment cytostatic drug steroid pretreatment ≥ 1 mg/kg/d two week last month diagnosis treatment start accord another protocol underlie disease prohibit treatment accord protocol ALL diagnose second malignancy steroid pretreatment ≥ 1 mg/kg/d two week last month diagnosis</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>